Univariate analysis
| Outcomes . | Haploidentical (1) . | URD without ATG (2) . | URD with ATG (3) . | Pairwise P . | Overall P . | ||||
|---|---|---|---|---|---|---|---|---|---|
| N Eval . | Prob % (95% CI) . | N Eval . | Prob % (95% CI) . | N Eval . | Prob % (95% CI) . | 1 vs 2 . | 1 vs 3 . | ||
| ANC recovery >500/μL | 184 | 482 | 236 | ||||||
| 28 d | 94 (90-97) | 97 (95-98) | 97 (94-99) | .17 | .15 | .32 | |||
| 100 d | 98 (95-99) | 98 (97-99) | 97 (95-99) | .98 | .51 | .74 | |||
| Platelet recovery ≥20/μL | 184 | 481 | 234 | ||||||
| 28 d | 63 (56-70) | 89 (86-92) | 84 (79-89) | <.001 | <.001 | <.001 | |||
| 100 d | 93 (89-97) | 96 (94-97) | 91 (88-95) | .25 | .43 | .08 | |||
| Acute GVHD (II-IV)* | 49 | 93 | 41 | ||||||
| 100 d | 27 (15-40) | 40 (30-50) | 49 (34-64) | .10 | .03 | .07 | |||
| Acute GVHD (III-IV)* | 49 | 93 | 41 | ||||||
| 100 d | 8 (2-17) | 12 (6-19) | 17 (7-30) | .48 | .21 | .44 | |||
| Acute GVHD (II-IV) | 180 | 482 | 235 | ||||||
| 180 d | 52 (44-60) | 60 (55-65) | 56 (49-63) | .13 | .47 | .29 | |||
| Chronic GVHD | 183 | 475 | 230 | ||||||
| 1 y | 13 (8-18) | 51 (46-55) | 33 (27-39) | <.001 | <.001 | <.001 | |||
| 2 y | 15 (10-21) | 62 (57-67) | 37 (31-44) | <.001 | <.001 | <.001 | |||
| NRM | 184 | 488 | 240 | ||||||
| 1 y | 11 (7-17) | 13 (10-16) | 20 (15-25) | .64 | .02 | .03 | |||
| 2 y | 16 (11-22) | 18 (15-22) | 24 (19-30) | .56 | .04 | .10 | |||
| 3 y | 17 (12-23) | 22 (18-27) | 26 (21-33) | .14 | .02 | .08 | |||
| Relapse/progression | 184 | 488 | 240 | ||||||
| 1 y | 30 (24-37) | 22 (18-26) | 27 (21-33) | .03 | .45 | .07 | |||
| 2 y | 34 (27-41) | 27 (23-31) | 32 (26-38) | .09 | .67 | .15 | |||
| 3 y | 36 (29-43) | 28 (24-33) | 36 (29-43) | .08 | .99 | .07 | |||
| PFS | 184 | 488 | 240 | ||||||
| 1 y | 58 (51-65) | 65 (61-70) | 53 (47-60) | .10 | .31 | .007 | |||
| 2 y | 50 (42-57) | 55 (50-60) | 44 (37-50) | .25 | .23 | .02 | |||
| 3 y | 47 (40-55) | 49 (44-54) | 38 (31-45) | .63 | .07 | .02 | |||
| OS | 185 | 491 | 241 | ||||||
| 1 y | 76 (69-81) | 78 (74-81) | 65 (58-71) | .57 | .01 | .002 | |||
| 2 y | 63 (56-71) | 69 (65-73) | 55 (49-62) | .18 | .11 | .003 | |||
| 3 y | 60 (52-67) | 62 (57-67) | 50 (42-57) | .65 | .05 | .02 | |||
| Outcomes . | Haploidentical (1) . | URD without ATG (2) . | URD with ATG (3) . | Pairwise P . | Overall P . | ||||
|---|---|---|---|---|---|---|---|---|---|
| N Eval . | Prob % (95% CI) . | N Eval . | Prob % (95% CI) . | N Eval . | Prob % (95% CI) . | 1 vs 2 . | 1 vs 3 . | ||
| ANC recovery >500/μL | 184 | 482 | 236 | ||||||
| 28 d | 94 (90-97) | 97 (95-98) | 97 (94-99) | .17 | .15 | .32 | |||
| 100 d | 98 (95-99) | 98 (97-99) | 97 (95-99) | .98 | .51 | .74 | |||
| Platelet recovery ≥20/μL | 184 | 481 | 234 | ||||||
| 28 d | 63 (56-70) | 89 (86-92) | 84 (79-89) | <.001 | <.001 | <.001 | |||
| 100 d | 93 (89-97) | 96 (94-97) | 91 (88-95) | .25 | .43 | .08 | |||
| Acute GVHD (II-IV)* | 49 | 93 | 41 | ||||||
| 100 d | 27 (15-40) | 40 (30-50) | 49 (34-64) | .10 | .03 | .07 | |||
| Acute GVHD (III-IV)* | 49 | 93 | 41 | ||||||
| 100 d | 8 (2-17) | 12 (6-19) | 17 (7-30) | .48 | .21 | .44 | |||
| Acute GVHD (II-IV) | 180 | 482 | 235 | ||||||
| 180 d | 52 (44-60) | 60 (55-65) | 56 (49-63) | .13 | .47 | .29 | |||
| Chronic GVHD | 183 | 475 | 230 | ||||||
| 1 y | 13 (8-18) | 51 (46-55) | 33 (27-39) | <.001 | <.001 | <.001 | |||
| 2 y | 15 (10-21) | 62 (57-67) | 37 (31-44) | <.001 | <.001 | <.001 | |||
| NRM | 184 | 488 | 240 | ||||||
| 1 y | 11 (7-17) | 13 (10-16) | 20 (15-25) | .64 | .02 | .03 | |||
| 2 y | 16 (11-22) | 18 (15-22) | 24 (19-30) | .56 | .04 | .10 | |||
| 3 y | 17 (12-23) | 22 (18-27) | 26 (21-33) | .14 | .02 | .08 | |||
| Relapse/progression | 184 | 488 | 240 | ||||||
| 1 y | 30 (24-37) | 22 (18-26) | 27 (21-33) | .03 | .45 | .07 | |||
| 2 y | 34 (27-41) | 27 (23-31) | 32 (26-38) | .09 | .67 | .15 | |||
| 3 y | 36 (29-43) | 28 (24-33) | 36 (29-43) | .08 | .99 | .07 | |||
| PFS | 184 | 488 | 240 | ||||||
| 1 y | 58 (51-65) | 65 (61-70) | 53 (47-60) | .10 | .31 | .007 | |||
| 2 y | 50 (42-57) | 55 (50-60) | 44 (37-50) | .25 | .23 | .02 | |||
| 3 y | 47 (40-55) | 49 (44-54) | 38 (31-45) | .63 | .07 | .02 | |||
| OS | 185 | 491 | 241 | ||||||
| 1 y | 76 (69-81) | 78 (74-81) | 65 (58-71) | .57 | .01 | .002 | |||
| 2 y | 63 (56-71) | 69 (65-73) | 55 (49-62) | .18 | .11 | .003 | |||
| 3 y | 60 (52-67) | 62 (57-67) | 50 (42-57) | .65 | .05 | .02 | |||
Probabilities of neutrophil and platelet recovery, platelet recovery, acute GVHD, chronic GVHD, treatment-related mortality, and progression/relapse were calculated using the cumulative incidence estimate. PFS and OS were calculated using the Kaplan-Meier product limit estimate.
Eval, evaluable; N, number; NA, not applicable; NE, not evaluable; Prob, probability.
Calculated from CRF-level data only.